EcoDrugPlus

Janus Kinase 2b

Ensembl ID : ENSOTSG00005036647
Gene Symbol: JAK2B
1 Cross references
194 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005026188
Gene Symbol: KIT
3 Cross references
198 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005019264
Gene Symbol: KIT
3 Cross references
198 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005030883
Gene Symbol: KIT
1 Cross references
198 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSOTSG00005042046
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 5

Ensembl ID : ENSOTSG00005015054
Gene Symbol: LOC112247401
3 Cross references
174 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSOTSG00005015493
Gene Symbol: MAPKAPK2
1 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSOTSG00005006808
Gene Symbol: MAPKAPK2B
1 Cross references
168 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSOTSG00005037107
Gene Symbol: MAPKAPK2B
1 Cross references
168 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSOTSG00005042038
Gene Symbol: MAPKAPK5
1 Cross references
173 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSOTSG00005016120
Gene Symbol: MKNK2B
1 Cross references
202 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSOTSG00005015720
Gene Symbol: MCL1B
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).